CIK 0001818331 · Large accelerated filer
GeneDx Holdings Corp.
Sign in to watch- Ticker
- WGS
- Exchange
- Nasdaq
- Industry
- Services-Health Services
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851966622
- Phone
- 888-729-1206
- Business address
- 333 LUDLOW STREET, NORTH TOWER, 6TH FLOOR, STAMFORD, CT, 06902
- Former names
- Sema4 Holdings Corp., CM Life Sciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,839,245
- in 5 filings
Net −$1,839,245. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-30 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −421 | $110.05 | $46K | 3,982 |
| 2025-09-30 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −520 | $111.93 | $58K | 3,462 |
| 2025-09-30 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −70 | $113.68 | $8K | 3,392 |
| 2025-09-30 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −1,246 | 4,982 | ||
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −606 | $105.10 | $64K | 13,972 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −1,092 | $106.69 | $117K | 12,880 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −4,462 | $107.61 | $480K | 8,418 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −5,163 | $108.55 | $560K | 3,255 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −554 | $109.13 | $60K | 2,701 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −200 | $110.23 | $22K | 2,501 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −645 | $111.84 | $72K | 1,856 |
| 2025-09-30 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −136 | $113.68 | $15K | 1,720 |
| 2025-09-17 | Fuchs Thomas Director | Grant or award · Restricted Stock Unit | −3,438 | 3,438 | ||
| 2025-09-16 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | +7,197 | 12,483 | ||
| 2025-09-16 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | −7,197 | 12,483 | ||
| 2025-09-16 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | −3,728 | $121.47 | $453K | 8,755 |
| 2025-09-16 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise · Restricted Stock Unit | −7,197 | 43,181 | ||
| 2025-09-16 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Option exercise | +18,750 | 25,079 | ||
| 2025-09-16 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | −10,501 | $121.47 | $1.3M | 14,578 |
| 2025-09-16 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Option exercise · Restricted Stock Unit | −18,750 | 112,500 |
Page 13 of 23 · 450 trades